After Novartis’ Pluvicto shook up iSpot.TV’s monthly rankings of the top TV advertising spenders in pharma to kick off the year ... Sanofi and Regeneron’s Dupixent, which climbed one ...

The French drugmaker is paying $17.5 million upfront to kick off the collaboration ... ambitions in immuno-oncology are spearheaded by its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo ...

The German group is paying $40 million upfront to kick off the alliance ... a rare form of blindness, and Intellia/Regeneron's NTLA-2001 transthyretin amyloidosis. While the main thrust of ...

Regeneron’s oncology therapy ... These treatments arenow moving to Phase 3, set to kick off in early 2025, potentially paving the way for more positive news. Wall Street is confident about ...

RIVERFEST Limerick 2025 will present a diverse range of activities and events designed to delight visitors of all ages from ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition, with Eylea HD showing strong performance and new innovations like a pre-filled syringe on the horizon. Dupixent ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court ...

The “kick-change” is hot, and it’s so new we can actually track its progress through the league. And maybe tracking that progress will tell us a little more about what it means to be a Pitch ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss. Last month, Regeneron ...

The S&P 500 Index ($SPX) (SPY) today is up +0.64%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.29%, and the Nasdaq ...